Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
St Louis, MO
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Somers Point, NJ
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Voorhees, NJ
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
New York, NY
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Rochester, NY
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Portland, OR
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Philadelphia, PA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Fort Worth, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Galveston, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Houston, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Hampton, VA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Hampton, VA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Spokane, WA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
mi
from
Ponce,
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
mi
from
Ponce,
Click here to add this to my saved trials
Human Immune Responses Toward HIV-1 Envelope Antigens
Human Immune Responses Toward HIV-1 Envelope Antigens
Status: Enrolling
Updated:  11/4/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Human Immune Responses Toward HIV-1 Envelope Antigens
Human Immune Responses Toward HIV-1 Envelope Antigens
Status: Enrolling
Updated: 11/4/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Phoenix, AZ
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Long Beach, CA
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
San Francisco, CA
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Denver, CO
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Washington,
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Fort Lauderdale, FL
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Orlando, FL
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Santa Fe, NM
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Santa Fe, NM
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Charlotte, NC
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Dallas, TX
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
mi
from
Toronto,
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Northwestern University CRS (2701)
mi
from
Chicago, IL
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Henry Ford Hosp. CRS (31472)
mi
from
Detroit, MI
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Henry Ford Hosp. CRS (31472)
mi
from
Detroit, MI
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Washington U CRS (2101)
mi
from
St. Louis, MO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Washington U CRS (2101)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cooper Univ. Hosp. CRS (31476)
mi
from
Camden, NJ
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cooper Univ. Hosp. CRS (31476)
mi
from
Camden, NJ
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cornell CRS (7804)
mi
from
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cornell CRS (7804)
mi
from
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Unc Aids Crs
mi
from
Chapel Hill, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Metro Health CRS (2503)
mi
from
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Metro Health CRS (2503)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Case CRS (2501)
mi
from
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Pitt CRS (1001)
mi
from
Pittsburgh, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Pitt CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Click here to add this to my saved trials